Literature DB >> 25860238

Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma.

Morihiro Higashi1, Michihide Tokuhira2, Satoshi Fujino1, Takahisa Yamashita1, Keiko Abe1, Eiichi Arai1, Masahiro Kizaki2, Jun-ichi Tamaru1.   

Abstract

The interaction between tumor cells and the tumor microenvironment is essential in the development and progression of diffuse large B-cell lymphoma (DLBCL). Loss of human leukocyte antigen DR (HLA-DR) in DLBCL is a robust adverse prognostic marker. We evaluated the immunohitochemical expression of HLA-DR in lymphoma and the biologic implications of the loss of HLA-DR. The loss of HLA-DR correlated with clinical stage (p < 0.05), International Prognosis Index (p < 0.05), soluble interleukin-2 receptor (p < 0.05) and poor outcome in patients with DLBCL, especially among elderly patients. Flow cytometry analysis of the infiltrating T-cells showed that the mean CD4 + CD25 +/CD8 ratio of the infiltrating T-cells was higher in the HLA-DR positive group than in the HLA-DR negative group (p < 0.05). These data suggest that loss of HLA-DR expression in DLBCL decreases the ratio of helper T-cell within the T-cell population in the tumor microenvironment and might contribute to escape from immunosurveillance.

Entities:  

Keywords:  Diffuse large B-cell lymphoma; HLA-DR; tumor microenvironment

Mesh:

Substances:

Year:  2015        PMID: 25860238     DOI: 10.3109/10428194.2015.1038708

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  9 in total

Review 1.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

Review 2.  Diffuse large B-cell lymphoma: R-CHOP failure-what to do?

Authors:  Bertrand Coiffier; Clémentine Sarkozy
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 3.  Developing T-cell therapies for lymphoma without receptor engineering.

Authors:  Melanie Grant; Catherine M Bollard
Journal:  Blood Adv       Date:  2017-12-08

Review 4.  Developing T-cell therapies for lymphoma without receptor engineering.

Authors:  Melanie Grant; Catherine M Bollard
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

5.  Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptor.

Authors:  Fan Fei; Liang Rong; Nan Jiang; Alan S Wayne; Jianming Xie
Journal:  Mol Ther       Date:  2021-11-18       Impact factor: 11.454

Review 6.  Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications.

Authors:  Sotirios G Papageorgiou; Thomas P Thomopoulos; Ioannis Katagas; Anthi Bouchla; Vassiliki Pappa
Journal:  Ther Adv Hematol       Date:  2021-05-24

7.  Circulating activated lymphocyte subsets as potential blood biomarkers of cancer progression.

Authors:  Ying-Yi Wang; Na Zhou; Hong-Sheng Liu; Xiao-Lei Gong; Rui Zhu; Xiao-Yuan Li; Zhao Sun; Xu-Hong Zong; Ning-Ning Li; Chang-Ting Meng; Chun-Mei Bai; Tai-Sheng Li
Journal:  Cancer Med       Date:  2020-05-27       Impact factor: 4.452

8.  CD24 is a surrogate for 'immune-cold' phenotype in aggressive large B-cell lymphoma.

Authors:  Morihiro Higashi; Shuji Momose; Natsuko Takayanagi; Yuka Tanaka; Tomoe Anan; Takahisa Yamashita; Jun Kikuchi; Michihide Tokuhira; Masahiro Kizaki; Jun-Ichi Tamaru
Journal:  J Pathol Clin Res       Date:  2022-03-14

9.  FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.

Authors:  P J Brown; K K Wong; S L Felce; L Lyne; H Spearman; E J Soilleux; L M Pedersen; M B Møller; T M Green; D M Gascoyne; A H Banham
Journal:  Leukemia       Date:  2015-10-26       Impact factor: 11.528

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.